<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795977</url>
  </required_header>
  <id_info>
    <org_study_id>198</org_study_id>
    <nct_id>NCT00795977</nct_id>
  </id_info>
  <brief_title>Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer</brief_title>
  <official_title>Phase I/II Study on Intratumor Dendritic Cell Injection Immunotherapy Using Immature Dendritic Cells With S Pyogenes Preparation (OK-432) for Patients With Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fukushima Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm safety and immunological responses of Preoperative
      intratumor dendritic cells injection immunotherapy using immature dendritic cells with S
      pyogenes Preparation (OK-432) for patients with resectable pancreatic cancer for pancreatic
      cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of pancreatic cancer is extremely poor even with extensive surgery, and
      development of new treatment modalities is much-expected for cure of this disease. Dendritic
      cells (DCs) immunotherapy is expected favorable outcome when it is approached directly to the
      cancer tissue. To evaluate safety and immunological responses, we conducted a phase I/II
      study of intra-tumor DCs immunotherapy for pancreatic cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the overall response rate for this regimen as determined by overall and disease-free survival.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dendritic cells, OK-432</intervention_name>
    <description>Single Group Assignment</description>
    <arm_group_label>dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Resectable pancreatic cancer without distant metastasis:

          1. ECOG performance status 0-2

          2. Laboratory values as follows 3,500/mm3 &lt;WBC&lt;12000/mm3 Platelet count&gt;100,000/mm3
             T-Bil&lt;2.0mg/dl BUN&lt;25mg/dl, Creatinin&lt;1.5mg/dl, 24h Ccr&gt;50ml/min Normal ECG

          3. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Pregnancy (women of childbearing potential: Refusal or inability to use effective
             means of contraception)

          2. Breast-feeder

          3. Active or uncontrolled infection

          4. Active or uncontrolled other malignancy

          5. Steroids or immunosuppressing agent dependant status

          6. Interstitial pneumonia

          7. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsukazu Gotoh, MD &amp; PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fukushima Medical University, Department of Surgery 1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Kanzaki N, Terashima M, Kashimura S, Hoshino M, Ohtani S, Matsuyama S, Hoshino Y, Kogure M, Oshibe I, Endo H, Saito T, Yaginuma H, Gotoh M, Ohto H. Understanding the response of dendritic cells to activation by streptococcal preparation OK-432. Anticancer Res. 2005 Nov-Dec;25(6B):4231-8.</citation>
    <PMID>16309221</PMID>
  </reference>
  <reference>
    <citation>Takekuni K, Sakon M, Kishimoto S, Amano M, Sekimoto M, Aoki T, Oosato H, Dohno K, Umeshita K, Gotoh M, Monden T, Monden M. [A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin]. Gan To Kagaku Ryoho. 1996 Sep;23(11):1621-3. Japanese.</citation>
    <PMID>8854822</PMID>
  </reference>
  <reference>
    <citation>Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 2004 Aug 1;64(15):5461-70.</citation>
    <PMID>15289356</PMID>
  </reference>
  <reference>
    <citation>Oshikawa T, Okamoto M, Ahmed SU, Tano T, Yoshida H, Sato M. [Anti-cancer effect of an intratumoral injection of dendritic cells expressing TLR4 in combination with an active component of OK-432 in TLR4-deficient mice]. Gan To Kagaku Ryoho. 2004 Oct;31(11):1770-2. Japanese.</citation>
    <PMID>15553710</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fukushima Medical University</investigator_affiliation>
    <investigator_full_name>Akira Kenjo</investigator_full_name>
    <investigator_title>Department of Surgery I</investigator_title>
  </responsible_party>
  <keyword>preoperative</keyword>
  <keyword>intratumor</keyword>
  <keyword>dendritic cells</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>OK-432</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Picibanil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 13, 2017</submitted>
    <returned>March 29, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

